RxDoctor Payments Data

Mary Fregene, PA

Physician Assistant · Holland, MINPI 1639361884

Payments from drug & device makers

$1,378in general payments, 2019–2025

Across 72 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$587
  • AbbVie$261
  • Madrigal Pharmaceuticals$143
  • Boston Scientific$113
  • Johnson & Johnson$80
  • E.r. Squibb & Sons, L.L.C.$51
  • plus $142 from 5 others

What the payments were for

  • Food & beverage$1,34598%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,378 in reported general payments places this provider in the 80th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$13,346
Medicare patients
101
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin38$116,345
Humira(Cf) PenAdalimumab14$106,697
CreonLipase/Protease/Amylase20$51,890
LinzessLinaclotide58$43,182
Mesalamine ErMesalamine29$21,014
Mesalamine37$20,838
IbsrelaTenapanor Hcl12$20,459
Balsalazide Disodium42$14,492
Ursodiol31$7,459
Lubiprostone32$4,437
Budesonide DrBudesonide37$4,425
Famotidine23$4,215
Pantoprazole Sodium126$2,955
Omeprazole95$2,355
Dicyclomine Hcl93$2,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$37$116,34538 claims
AbbVieCreon, Linzess$261$95,07178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →